AKESF Financials: Akeso Inc AI Analysis

Home

Stock

AKESF

Financials

AKESF Financial

Akeso Inc

$18.5

5.11%

$0.89

At close: Apr 02, 16:00:00 GMT-4

$18.5

Post-market: Apr 02, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

AKESF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	3,056	3,056	2,123	4,526	837	225
Revenue Growth (YoY)	44%	44%	-53%	441%	272%	--
Cost of Revenue	668	652	301	137	103	30
Gross Profit	2,388	2,403	1,822	4,388	734	195
Selling, General & Admin	1,732	1,732	1,205	1,089	749	421
Research & Development	1,575	1,575	1,187	1,254	1,323	1,122
Operating Expenses	3,210	3,096	2,497	2,475	2,111	1,471
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-1,140	-1,140	-501	1,942	-1,422	-1,258
Income Tax Expense	0	0	0	0	0	0
Net Income	-1,113	-1,113	-514	2,028	-1,168	-1,074
Net Income Growth	117%	117%	-125%	-274%	9%	4%
Shares Outstanding (Diluted)	910.54	902.86	851.02	837.82	824.98	815.93
Shares Change (YoY)	6%	6%	2%	2%	1%	30%
EPS (Diluted)	-1.23	-1.23	-0.6	2.42	-1.41	-1.31
EPS Growth	104%	104%	-125%	-271%	8%	-20%
Free Cash Flow	--	--	-1,121	1,588	-2,042	-1,717
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	78.14%	78.63%	85.82%	96.95%	87.69%	86.66%
Operating Margin	-26.89%	-22.64%	-31.79%	42.26%	-164.39%	-566.66%
Profit Margin	-36.42%	-36.42%	-24.21%	44.8%	-139.54%	-477.33%
Free Cash Flow Margin	--	--	-52.8%	35.08%	-243.96%	-763.11%
EBITDA	--	--	-673	1,915	-1,374	-1,274
EBITDA Margin	--	--	-31.7%	42.31%	-164.15%	-566.22%
D&A For EBITDA	--	--	2	2	2	1
EBIT	-822	-692	-675	1,913	-1,376	-1,275
EBIT Margin	-26.89%	-22.64%	-31.79%	42.26%	-164.39%	-566.66%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Key Stats

Prev.Close

$17.6

Open

$18.5

Day's Range

$18.5 - $18.5

52 week range

$8.25 - $23.15

Volume

Avg.Volume

1.7K

Dividend yield

EPS (TTM)

-0.14

Market Cap

$17.0B

What is AKESO INC.?

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong and currently employs 3,529 full-time employees. The company went IPO on 2020-04-24. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The firm's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.



Features

AI Copilot for Stock & Crypto

Resources